Analyst Actions

Canaccord Genuity Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $18

Oct 26, 2026 · 08:18 AM ET· updated 11h ago

Canaccord Genuity analyst Gary Nachman initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy rating and announces Price Target of $18.

Why It Matters

A big investment research firm started following Tonix Pharmaceuticals and says it looks good. They picked a target price to help investors understand what they think it could be worth.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

TNXP5.30

+0.13 (+2.51%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.